PACAP-27 vs Adiponectin
Head-to-head comparison of PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) and Adiponectin (Adiponectin (Acrp30, AdipoQ)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | PACAP-27 | Adiponectin |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Pituitary Adenylate Cyclase-Activating Polypeptide-27 | Adiponectin (Acrp30, AdipoQ) |
| Molecular Weight | 3158 Da | ~26.4 kDa (monomer) |
| Half-Life | minutes | ~2-4 h |
| Amino Acids | 27 | 244 |
| Typical Dose | Research-only: 0.1-1 nmol/kg | No approved human dose; research use only |
| Route | Intraperitoneal/Subcutaneous | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 220 | 86 |
| Research Status | Pre-clinical | Pre-clinical |
PACAP-27 Benefits
- ✓anti-apoptotic signaling
- ✓insulin secretagogue effect
- ✓reduced ER stress
- ✓islet cytoprotection
Adiponectin Benefits
- ✓insulin sensitivity
- ✓fatty-acid oxidation
- ✓AMPK activation
PACAP-27 Dosing
0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing
Adiponectin Dosing
not established|not established
PACAP-27 Side Effects
- ⚠flushing
- ⚠hypotension at high exposure
- ⚠headache
Adiponectin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
PACAP-27
PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.
Adiponectin
Preclinical and translational studies link adiponectin signaling with better glycemic control, lower inflammation, and improved lipid handling. Recombinant adiponectin and receptor-targeting approaches remain research tools rather than approved diabetes therapies.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.